SCHEMBL4281805

SCHEMBL4281805

CCOC(=O)n1nc(NC(=O)c2ccc(N3CCN(C)CC3)c(F)c2)c2c1C(C)(C)N(S(=O)(=O)c1cc(F)cc(F)c1)C2

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.54
NTRK1 P04629 3/20 0.39
NTRK3 Q16288 2/20 0.39
NTRK2 Q16620 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPT P10636 4/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
WDR5 P61964 3/20 0.38
FGFR1 P11362 1/20 0.37
FGFR2 P21802 1/20 0.37
HSD17B10 Q99714 2/20 0.37
TSHR P16473 2/20 0.37
LMNA P02545 2/20 0.37
NPC1 O15118 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
ALOX15 P16050 1/20 0.37
MAPK1 P28482 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4281921 0.91 IGF1R (0.51) IGF1RL3MBTL1MAPTMEN1KMT2A
SCHEMBL13857360 0.83 L3MBTL1 (0.42) IGF1RNTRK1NTRK3NTRK2L3MBTL1
SCHEMBL4282010 0.81 L3MBTL1 (0.44) IGF1RNTRK1NTRK3NTRK2L3MBTL1
SCHEMBL4278137 0.80 IGF1R (0.79) IGF1RNTRK1NTRK3NTRK2CCNA2
SCHEMBL1372432 0.79 IGF1R (0.35) IGF1RNTRK1MAPTKMT2AHSD17B10
SCHEMBL1371183 0.78 IGF1R (0.34) IGF1RL3MBTL1MAPTMEN1KMT2A
SCHEMBL4291575 0.78 IGF1R (0.49) IGF1RNTRK1NTRK3NTRK2MAPT
SCHEMBL1374649 0.74 IGF1R (0.40) IGF1RNTRK1MAPTKMT2AHSD17B10
SCHEMBL4279723 0.73 IGF1R (0.40) IGF1RNTRK1NTRK3NTRK2MEN1
SCHEMBL4287268 0.73 TAAR1 (0.42) IGF1RNTRK1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
US-9012487-B2 Bicyclo-pyrazoles active as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2015-04-21 US disclosed
EP-1999131-B1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-10-23 EP disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L (IT) 2009-05-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136513-A1 BICYCLO-PYRAZOLES ACTIVE AS KINASE INHIBITORS MAP3K19, CDK2, MAP3K1 IGF1R 530/4885NTRK1 1106/4885NTRK3 892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.